Scholarlink

Background <p>Diabetic keratopathy (DK) is a sight-threatening complication affecting up to 70% of diabetic patients, for which there are currently no effective therapies to halt disease progression. This study seeks to identify a novel DK biomarker and characterize its mechanistic role in disease pathogenesis.</p> Methods <p>Proteomic analysis was performed on conjunctival epithelial cells from diabetic patients with and without DK using iTRAQ labeling coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Differential protein expression was validated in diabetic mouse models, human diabetic corneas, and high glucose-induced epithelial cell models. The role of nicotinamide phosphoribosyltransferase (NAMPT) in regulating mitophagy in corneal epithelial cells was further investigated through genetic manipulation. The protective effects of the NAMPT activator P7C3 on corneal nerves and epithelium were evaluated in db/db mice.</p> Results <p>NAMPT was identified as a differentially expressed protein. Chronic hyperglycemia selectively depleted mitochondrial NAMPT in corneal epithelial cells, disrupting nicotinamide adenine dinucleotide (NAD) biosynthesis and triggering a self-amplifying cycle of oxidative stress and impaired PINK1-mediated mitophagy, ultimately leading to apoptosis. In diabetic db/db mice, topical application of the NAMPT activator P7C3 enhanced NAMPT activity, restored mitochondrial quality control, attenuated epithelial degeneration, reduced stromal edema, restored tear secretion, and promoted regeneration of corneal nerves and epithelium.</p> Conclusions <p>Mitochondrial localization of NAMPT expression loss is a central driver of DK pathogenesis. Topical application of the NAMPT activator P7C3 holds promise for restoring both corneal homeostasis and tear secretion function, making it a novel therapeutic target for oxidative stress-related corneal diseases and Diabetic Dry Eye Syndrome.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Topical NAMPT activation restores mitophagic flux to rescue diabetic keratopathy via the NAD⁺/PINK1 pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月9日

查看全文
  • Qian Guo,
  • Guannan Huang,
  • Wanting Li,
  • Yunjing Ma,
  • Haini Liu,
  • Zihao Liu,
  • Limin Zhu,
  • Lechong Ma,
  • Qingjun Zhou,
  • Shaozhen Zhao

摘要

Background

Diabetic keratopathy (DK) is a sight-threatening complication affecting up to 70% of diabetic patients, for which there are currently no effective therapies to halt disease progression. This study seeks to identify a novel DK biomarker and characterize its mechanistic role in disease pathogenesis.

Methods

Proteomic analysis was performed on conjunctival epithelial cells from diabetic patients with and without DK using iTRAQ labeling coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Differential protein expression was validated in diabetic mouse models, human diabetic corneas, and high glucose-induced epithelial cell models. The role of nicotinamide phosphoribosyltransferase (NAMPT) in regulating mitophagy in corneal epithelial cells was further investigated through genetic manipulation. The protective effects of the NAMPT activator P7C3 on corneal nerves and epithelium were evaluated in db/db mice.

Results

NAMPT was identified as a differentially expressed protein. Chronic hyperglycemia selectively depleted mitochondrial NAMPT in corneal epithelial cells, disrupting nicotinamide adenine dinucleotide (NAD) biosynthesis and triggering a self-amplifying cycle of oxidative stress and impaired PINK1-mediated mitophagy, ultimately leading to apoptosis. In diabetic db/db mice, topical application of the NAMPT activator P7C3 enhanced NAMPT activity, restored mitochondrial quality control, attenuated epithelial degeneration, reduced stromal edema, restored tear secretion, and promoted regeneration of corneal nerves and epithelium.

Conclusions

Mitochondrial localization of NAMPT expression loss is a central driver of DK pathogenesis. Topical application of the NAMPT activator P7C3 holds promise for restoring both corneal homeostasis and tear secretion function, making it a novel therapeutic target for oxidative stress-related corneal diseases and Diabetic Dry Eye Syndrome.